Immunogenicity and safety of heterologous and homologous prime-boost schedules with an adenoviral vectored and inactivated SARS-CoV-2 (COVID-19) vaccines

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20210913001

Enrollment

400

Registered

2021-09-13

Start date

2021-09-30

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 COVID-19 Inactivated vaccine Viral vectored vaccine

Interventions

Participants who received one dose of CoronaVac and one dose of ChAdOx1-S nCoV-19 ,Participants who received two doses of ChAdOx1-S nCoV-19

Prevention,Prevention

CoronaVac/ChAd,ChAd/ChAd

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Thai nationality 2. Received one dose of CoronaVac 3-4 weeks prior or one dose of ChAdOx1-S nCoV-19 4-12 weeks prior

Exclusion criteria

Exclusion criteria: 1. Prior COVID-19 infection 2. Allergic to vaccine or vaccine component 3. Receiving immunosuppressants, immunoglobulin or blood components within 3 months 4. Anatomical or functional asplenia 5. Drug abuse or alcoholism 6. Autoimmune or immunodeficiency diseases 7. Pregnancy or lactation

Design outcomes

Primary

Measure	Time frame
Immunogenicity At 28 days after second vaccination SARS-CoV-2 anti-spike IgG titer	—

Secondary

Measure	Time frame
Immunogenicity At 28 and 90 days after second vaccination SARS-CoV-2 anti-spike IgG titer, SARS-CoV-2 surrogate neutralizing antibody,Adverse events Within 90 days after second vaccination Patient reported outcome using a questionnaire interview	—

Countries

Thailand

Contacts

Public ContactPawat Phuensan

King Chulalongkorn Memorial Hospital

pawat.phuensan@gmail.com0815625652

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026